Drug Profile
Research programme: wound healing therapy - TA Therapeutics
Alternative Names: Wound healing therapy research programme - TA TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Geron Corporation; TA Therapeutics
- Class Gene therapies; Small molecules
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Wounds
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Wounds in USA
- 12 Mar 2010 Preclinical development is ongoing in USA
- 29 Jul 2003 This programme is still in active development